Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.

Le Teuff, Gwénaël; Cozic, Nathalie; Boyer, Jean-Christophe; Boige, Valérie; Diasio, Robert B; Taieb, Julien; Meulendijks, Didier; Palles, Claire; Schwab, Matthias; Deenen, Maarten; Largiadèr, Carlo R; Marinaki, Anthony; Jennings, Barbara A; Wettergren, Yvonne; Di Paolo, Antonello; Gross, Eva; Budai, Barna; Ackland, Stephen P; van Kuilenburg, André B P; McLeod, Howard L; ... (2024). Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. British journal of cancer, 130(5), pp. 808-818. Springer Nature 10.1038/s41416-023-02517-2

Text s41416-023-02517-2.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (1MB) | Request a copy

BACKGROUND

Dihydropyrimidine dehydrogenase (DPD) deficiency is the main known cause of life-threatening fluoropyrimidine (FP)-induced toxicities. We conducted a meta-analysis on individual patient data to assess the contribution of deleterious DPYD variants *2A/D949V/*13/HapB3 (recommended by EMA) and clinical factors, for predicting G4-5 toxicity.

METHODS

Study eligibility criteria included recruitment of Caucasian patients without DPD-based FP-dose adjustment. Main endpoint was 12-week haematological or digestive G4-5 toxicity. The value of DPYD variants *2A/p.D949V/*13 merged, HapB3, and MIR27A rs895819 was evaluated using multivariable logistic models (AUC).

RESULTS

Among 25 eligible studies, complete clinical variables and primary endpoint were available in 15 studies (8733 patients). Twelve-week G4-5 toxicity prevalence was 7.3% (641 events). The clinical model included age, sex, body mass index, schedule of FP-administration, concomitant anticancer drugs. Adding *2A/p.D949V/*13 variants (at least one allele, prevalence 2.2%, OR 9.5 [95%CI 6.7-13.5]) significantly improved the model (p < 0.0001). The addition of HapB3 (prevalence 4.0%, 98.6% heterozygous), in spite of significant association with toxicity (OR 1.8 [95%CI 1.2-2.7]), did not improve the model. MIR27A rs895819 was not associated with toxicity, irrespective of DPYD variants.

CONCLUSIONS

FUSAFE meta-analysis highlights the major relevance of DPYD *2A/p.D949V/*13 combined with clinical variables to identify patients at risk of very severe FP-related toxicity.

Interest & Impact

Downloads

1 since deposited on 16 Jan 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item